The estimated Net Worth of Michael Kaseta is at least $3.5 Milion dollars as of 30 August 2024. Mr Kaseta owns over 2,344 units of Liquidia Corp stock worth over $3,207,877 and over the last 7 years he sold LQDA stock worth over $287,131.
Mr has made over 13 trades of the Liquidia Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,344 units of LQDA stock worth $23,792 on 30 August 2024.
The largest trade he's ever made was buying 18,700 units of Liquidia Corp stock on 31 May 2022 worth over $74,987. On average, Mr trades about 3,257 units every 43 days since 2017. As of 30 August 2024 he still owns at least 316,047 units of Liquidia Corp stock.
You can see the complete history of Mr Kaseta stock trades at the bottom of the page.
Michael Kaseta is the Chief Financial Officer at Liquidia Corp.
Mr Kaseta is 45, he's been the Chief Financial Officer of Liquidia Corp since . There are 18 older and 1 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: